McKesson reported 403.4 billion dollars of consolidated revenue in fiscal 2026 and, as of 31 March 2026, employed more than 43,000 people worldwide. That is roughly nine million dollars of revenue per employee, and it is the most useful fact a seller can hold in mind here.
Because the second number tells you what the first one is not. McKesson's North American Pharmaceutical segment turned 336.7 billion dollars of fiscal 2026 revenue into 3.5 billion dollars of adjusted segment operating profit, about one cent of operating profit per dollar of product moved. A distributor running on that spread does not evaluate your software the way a bank or a health system does. Every recurring vendor cost is a direct claim on a margin measured in basis points, and the person defending your line item knows it.
McKesson is also an unusual account because it is itself a supplier. Its customers are pharmacies, health systems and community specialty practices. Sales to its largest customer, CVS Health, accounted for approximately 24 percent of total consolidated revenues in fiscal 2026, and its ten largest customers, including group purchasing organisations, accounted for approximately 73 percent. Anything touching order accuracy, product availability or traceability is not an internal efficiency project. It sits on top of a customer concentration McKesson discloses as a risk factor.
How the buying process actually runs
Supplier registration runs through STARS, McKesson's own portal. There is no SAP Ariba or Coupa front door here. McKesson asks prospective vendors to register on STARS and states plainly that successful registration is not a guarantee of business or a promise of future consideration. The database is a search tool for its procurement teams when they are already looking. Registering is a prerequisite, not a pipeline.
Know whether you are Direct or Indirect first. McKesson looks for vendors supporting both sides. Direct means product that moves through the distribution network and is resold. Indirect means everything McKesson consumes itself. Different buyers, different budgets, different economics. Pitching an Indirect category to a Direct sourcing leader loses the meeting before it starts.
Regulatory gates apply to anything near the drug supply chain. The Drug Supply Chain Security Act requires standardised, unit-level traceability of pharmaceutical products along the entire chain, and requires trading partners to cooperate in an electronic, interoperable traceability system. McKesson also holds DEA and state-level registrations, must meet security and operating standards under the Controlled Substances Act, and states in its annual report that it maintains extensive controlled substance monitoring and reporting programmes at considerable expense. If your product touches inventory data, order flow or warehouse operations, diligence will involve compliance and legal, not just IT.
The purchase originates in a segment. McKesson reports four: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The structure is actively moving. McKesson completed its exit from European operations with the sale of its Norwegian retail and distribution businesses on 30 January 2026, and has signed a definitive agreement under which Apollo Global will acquire an approximately 13 percent minority interest in Medical-Surgical Solutions ahead of a planned separation.
Who owns what, so you know where your deal belongs
You will not be selling to these people. Their remit tells you which segment your deal sits inside and whose priorities it has to survive two or three levels down.
| Name | Role | What it means for a vendor |
|---|---|---|
| Kirk Kaminsky | Executive Vice President, Group President, North American Pharmaceutical Services | The centre of gravity for distribution volume, covering both the North American Pharmaceutical and Oncology and Multispecialty segments |
| Francisco Fraga | Executive Vice President, Chief Information Officer and Chief Technology Officer | Enterprise technology standards, warehouse automation and the architecture any Indirect software purchase has to fit |
| Kevin Kettler | Executive Vice President, President, Prescription Technology Solutions | The highest-margin part of the portfolio and the place a technology or data product is most likely to be bought rather than absorbed |
| Jason Hammonds | President, Oncology and Multispecialty | Specialty distribution, provider solutions and the practice-facing businesses, a different buyer from core wholesale |
| Kenny Cheung | Executive Vice President and Chief Financial Officer | Where a multi-year commitment has to clear a margin structure measured in fractions of a cent |
Brian Tyler is Chief Executive Officer and, since May 2026, Chair of the Board. Joan Eliasek is President, North American Pharmaceutical Distribution, and Stanton McComb is President, Medical-Surgical, the segment being separated. Names taken from McKesson's own leadership page, verified 11 September 2026. Senior roles change. Verify at source before using any name.
You cannot sell into this account from the bottom
Do the arithmetic from McKesson's side. A one million dollar annual software commitment has to be justified against a segment that produced 3.5 billion dollars of adjusted operating profit on 336.7 billion dollars of revenue. Every recurring cost at a distributor is a direct claim on a spread that is already measured in basis points, so approval sits higher than the equivalent purchase would at a company with normal gross margins.
That is the trap in this account. The easiest replies come from people who genuinely cannot approve the spend, and the altitude your entry point has to reach is higher than the size of the deal would suggest anywhere else.
The layer that matters is below the published names, and here it is operational
Twelve people appear on McKesson's Executive Operating Team page. They are easy to name and are not who you sell to.
The sponsors sit one level down, and at a distributor that layer is unusually operational rather than functional. It is the people running the 27 United States distribution centres in the North American Pharmaceutical network, including two strategic redistribution centres. It is the sourcing leads on the Direct side, where the ten largest suppliers accounted for approximately 71 percent of total purchases in fiscal 2026, and where generic sourcing runs partly through ClarusONE, a joint venture with Walmart. It is the compliance leadership that owns DSCSA and controlled substance monitoring. Almost none of these people appear on any published page, and their titles are physical and regional rather than corporate, which is exactly why a buying committee here is hard to map from the outside.
The board is a published second-degree map
This is the most useful asset on this page, because it is public, checkable, and almost nobody uses it. McKesson's eleven director nominees in the 2026 proxy statement, and where they sit elsewhere:
- Dominic J. Caruso, Lead Independent Director since May 2026, formerly Executive Vice President and Chief Financial Officer of Johnson and Johnson. Current public board: Kyndryl Holdings.
- Lynne M. Doughtie, formerly Chair and Chief Executive Officer of KPMG US. Current public boards: Boeing and Workday.
- W. Roy Dunbar, formerly Chief Executive Officer and Chairman of Network Solutions, and earlier president of global technology and operations at MasterCard and Chief Information Officer at Eli Lilly. Current public boards: Duke Energy, Johnson Controls International and SiteOne Landscape Supply.
- Deborah Dunsire, formerly President and Chief Executive Officer of H. Lundbeck. Current public board: Ultragenyx Pharmaceutical.
- Julie Gerberding, currently Chief Executive Officer of the Foundation for the National Institutes of Health, formerly director of the Centers for Disease Control and chief patient officer at Merck.
- James H. Hinton, currently an operating partner at Welsh, Carson, Anderson and Stowe, formerly Chief Executive Officer of Baylor Scott and White Health. Current public board: AMN Healthcare Services.
- Bradley E. Lerman, formerly Executive Vice President and Chief Legal Officer of Starbucks and, before that, general counsel of Medtronic.
- Maria N. Martinez, formerly Executive Vice President and Chief Operating Officer of Cisco Systems. Current public boards: Bank of America and Tyson Foods.
- Kevin M. Ozan, formerly Executive Vice President and Chief Financial Officer of McDonald's. Current public board: The Hershey Company.
- Brian S. Tyler, Chief Executive Officer and Chair of McKesson. Current public board: Republic Services.
- Kathleen Wilson-Thompson, formerly Executive Vice President and Global Chief Human Resources Officer of Walgreens Boots Alliance. Current public boards: Tesla and Wolverine Worldwide.
Read that as a seller. If anyone in your network is senior at Kyndryl, Boeing, Workday, Duke Energy, Johnson Controls, SiteOne, Ultragenyx, AMN Healthcare, Bank of America, Tyson Foods, Hershey, Republic Services, Tesla, Wolverine Worldwide, Welsh Carson or the Foundation for the NIH, there is a two-hop path to a McKesson director. Note also what is not on that list: no serving chief executive of a hospital system or a health plan. This is a board weighted towards supply chain, finance, compliance and regulated-industry operations, which is a reasonable proxy for what McKesson actually worries about.
Other connector routes into this account
McKesson does not publish a formal alumni programme of the kind some large employers run, so the usual alumni play needs a McKesson-specific substitute. Three exist.
Divestiture and separation alumni. McKesson has spent several years shrinking its perimeter: the European businesses were exited completely with the Norway sale in January 2026, and Medical-Surgical Solutions is being separated with Apollo Global taking a minority stake. Every one of those transitions produced people who still know people inside. This is a larger and fresher pool at McKesson than at most companies of its size.
Customers and acquired practice networks. The US Oncology Network, PRISM Vision Group and the Sarah Cannon Research Institute partnership all connect McKesson to clinician and practice leadership who are not McKesson employees but talk to McKesson constantly. A warm referral from a practice leader inside one of those networks lands differently from one sent by a vendor.
Suppliers, not just customers. Because McKesson's ten largest suppliers represent roughly 71 percent of its purchases, manufacturer-side relationships are unusually concentrated and unusually valuable. If you sell to large pharmaceutical manufacturers, you already share rooms with people who negotiate with McKesson quarterly.
Finding which of those paths your company actually has is what a relationship intelligence platform is for. The routes exist. At most companies nobody has ever run the query.
The internal ask, and the cost of getting it wrong
The step that fails more introductions is not the external one. Suppose your best path runs through one of your own board members who also sits on a board with a McKesson director. That is close to the strongest path available and it is close to unrepeatable. You have to get that person to prioritise it, write something credible, and spend a piece of a relationship built over years, on you. Ask twice in a quarter and you will not be asked again.
The same applies to a manufacturer contact or a practice leader. You are asking them to lend you professional credibility inside an industry where everyone negotiates with everyone. Two of your reps approaching the same connector about McKesson in the same month is common and entirely invisible unless somebody is tracking it.
Three rules for the introduction itself
Ask for the segment, not the company. "An introduction to whoever owns sourcing for Indirect technology in North American Pharmaceutical Services" is actionable. "An introduction to McKesson" is not.
Write the paragraph your connector will forward. They will not write your pitch, and at this margin structure it has to lead with cost or with customer service levels, not with innovation. The forwardable blurb is the whole craft.
A warm path starts the clock, it does not skip it. You still register in STARS, still clear security and compliance review, and still answer questions about DSCSA and controlled substance exposure if your product goes anywhere near the supply chain. What you get is a real conversation with someone who has the problem and the budget, several quarters earlier than you would otherwise.
See the warm paths into McKesson
Everything above describes the problem: distribution margins thin enough that every vendor cost gets read twice. What it does not tell you is which of your own relationships already reaches inside. That is a question about your network, not theirs, and it is the one most teams answer from memory.
Boomerang maps the warm paths your company already has into accounts like McKesson, across your team, your customers, your board and investors, and your partners. It then drafts the ask, routes it through the right connector and tracks it to a booked meeting. Book a 15-minute walkthrough and see it run against your own target accounts.
Frequently asked questions
How do you become a supplier to McKesson?
Register on STARS, McKesson's own online supplier portal. McKesson states directly that successful registration is not a guarantee of business or a promise of future consideration, and that the database is used by its procurement teams to search for vendors when they are already looking. There is no Ariba or Coupa front door. Before you register, work out whether you are a Direct supplier, meaning product that moves through the distribution network, or an Indirect supplier, meaning something McKesson consumes itself. They are different buyers with different budgets.
Who makes technology buying decisions at McKesson?
Purchases originate inside a segment rather than centrally. McKesson reports four: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions, the last of which is being separated. Francisco Fraga is Executive Vice President, Chief Information Officer and Chief Technology Officer, and enterprise standards sit with him, but a technology purchase is usually sponsored by an operating leader inside a segment, under executives such as Kirk Kaminsky for North American Pharmaceutical Services or Kevin Kettler for Prescription Technology Solutions.
Why is selling to a distributor different from selling to a hospital system or a health plan?
Margin structure. McKesson is not a payer and carries no insurance risk. Its North American Pharmaceutical segment produced 3.5 billion dollars of adjusted segment operating profit on 336.7 billion dollars of fiscal 2026 revenue, so roughly one cent of operating profit per dollar of product moved. Every recurring vendor cost is a direct claim on that spread, which pushes approval higher in the organisation than the deal size alone would suggest and makes cost-per-unit-shipped a more persuasive argument than almost anything else.
What regulatory requirements apply to a McKesson vendor?
Anything touching the pharmaceutical supply chain runs into the Drug Supply Chain Security Act, which requires standardised, unit-level traceability along the entire chain and an electronic, interoperable traceability system across trading partners. McKesson also holds DEA and state-level registrations, must meet security and operating standards under the Controlled Substances Act, and says in its annual report that it maintains extensive controlled substance monitoring and reporting programmes at considerable expense. Expect compliance and legal in your diligence, not only IT and procurement.
Can you cold email a McKesson executive?
You can, and the usual outcome is silence rather than rejection. McKesson generated 403.4 billion dollars of fiscal 2026 revenue with just over 43,000 employees, so the leverage on each senior person's calendar is extreme by any standard and those calendars are actively managed. The practical route is a different sender. McKesson's board is published and its directors sit on boards including Boeing, Workday, Bank of America, Tyson Foods, Hershey, Tesla, Duke Energy and Republic Services, which makes a second-degree path checkable rather than hypothetical.
